HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert N Willette Selected Research

6- (5- ((cyclopropylamino)carbonyl)- 3- fluoro- 2- methylphenyl)- N- (2,2- dimethylprpyl)- 3- pyridinecarboxamide

8/2020Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis.
9/2012Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.
2/2011Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.
9/2009Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert N Willette Research Topics

Disease

13Hypertrophy
08/2021 - 03/2004
9Myocardial Infarction
01/2020 - 06/2002
9Heart Failure
11/2019 - 03/2004
9Cardiomegaly (Heart Hypertrophy)
01/2017 - 09/2003
9Infarction (Infarctions)
07/2014 - 06/2002
8Cardiovascular Diseases (Cardiovascular Disease)
08/2021 - 09/2003
8Inflammation (Inflammations)
01/2019 - 12/2003
7Fibrosis (Cirrhosis)
11/2021 - 04/2005
7Reperfusion Injury
05/2017 - 02/2004
7Myocardial Ischemia (Ischemic Heart Diseases)
01/2015 - 02/2004
7Hypertension (High Blood Pressure)
01/2013 - 12/2003
6Stroke (Strokes)
01/2017 - 12/2003
6Atherosclerosis
09/2012 - 12/2003
5Cardio-Renal Syndrome
08/2021 - 01/2017
5Ischemia
01/2015 - 02/2004
4Albuminuria
01/2019 - 12/2003
3Dyslipidemias (Dyslipidemia)
01/2013 - 05/2008
3Hypercholesterolemia
02/2011 - 12/2003
3Hypoxia (Hypoxemia)
08/2010 - 09/2003
3Atherosclerotic Plaque (Atheroma)
02/2010 - 04/2005
2Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
08/2021 - 01/2007
2Chronic Renal Insufficiency
05/2021 - 01/2019
2Necrosis
05/2021 - 03/2019
2Proteinuria
08/2020 - 04/2005
2Heart Diseases (Heart Disease)
01/2014 - 03/2004
2Body Weight (Weight, Body)
10/2013 - 01/2013
2Acute Coronary Syndrome
10/2013 - 06/2002
2Vascular System Injuries
11/2010 - 04/2002
2Abdominal Aortic Aneurysm
08/2009 - 11/2008
2Essential Hypertension
03/2004 - 05/2003
1Lung Injury
11/2021
1Idiopathic Pulmonary Fibrosis
11/2021
1Pulmonary Fibrosis (Fibrosing Alveolitis)
11/2021
1Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal)
08/2020
1Left Ventricular Dysfunction
01/2020
1Brain Injuries (Brain Injury)
01/2017
1Brain Infarction
01/2017
1Cognitive Dysfunction
01/2017
1Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/2017
1Ventilator-Induced Lung Injury
07/2014
1Pneumonia (Pneumonitis)
07/2014

Drug/Important Bio-Agent (IBA)

14p38 Mitogen-Activated Protein KinasesIBA
08/2020 - 04/2002
6SaltsIBA
01/2012 - 12/2003
5MAP Kinase Kinase Kinase 5IBA
01/2021 - 01/2017
5Angiotensin IIIBA
05/2017 - 09/2003
5CytokinesIBA
07/2014 - 04/2002
46- (5- ((cyclopropylamino)carbonyl)- 3- fluoro- 2- methylphenyl)- N- (2,2- dimethylprpyl)- 3- pyridinecarboxamideIBA
08/2020 - 09/2009
4CollagenIBA
01/2020 - 01/2017
3Proteins (Proteins, Gene)FDA Link
05/2021 - 01/2017
3Biomarkers (Surrogate Marker)IBA
01/2019 - 09/2012
3Glucagon-Like Peptide 1 (GLP 1)IBA
01/2015 - 01/2011
3ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA
08/2009 - 04/2005
3Contrast MediaIBA
08/2009 - 04/2005
3SB 239063IBA
05/2005 - 04/2002
2IndicanIBA
05/2021 - 01/2017
2Phosphotransferases (Kinase)IBA
11/2019 - 01/2017
2Phenylephrine (Neo-Synephrine)FDA LinkGeneric
11/2019 - 05/2017
2Fatty Acids (Saturated Fatty Acids)IBA
01/2019 - 01/2015
2N- ((1- (cyclopropylethyl)- 6- fluoro- 4- hydroxy- 2- oxo- 1,2- dihydro- 3- quinolinyl)carbonyl)glycineIBA
01/2017 - 08/2010
2Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
01/2017 - 08/2010
2TRPC6 Cation ChannelIBA
01/2014 - 09/2013
2ReninIBA
01/2013 - 09/2009
2Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
09/2012 - 11/2010
2NG-Nitroarginine Methyl Ester (L-NAME)IBA
08/2008 - 04/2005
2PPAR deltaIBA
05/2008 - 07/2007
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2007 - 04/2002
2SB-239063ANIBA
04/2005 - 12/2003
2PPAR-gamma AgonistsIBA
04/2004 - 12/2003
2Peroxisome Proliferator-Activated Receptors (PPAR)IBA
04/2004 - 12/2003
2urotensin IIIBA
03/2004 - 05/2003
2Vasoconstrictor AgentsIBA
03/2004 - 05/2003
2Neurotransmitter Agents (Neurotransmitter)IBA
12/2003 - 09/2003
1Bleomycin (Blenoxane)FDA LinkGeneric
11/2021
1Phosphates (Orthophosphate)IBA
08/2021
1Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
08/2021
1Fibroblast Growth Factor-23IBA
08/2021
1Transforming Growth Factors (Transforming Growth Factor)IBA
05/2021
1Angiopoietin-2IBA
05/2021
1Tissue Inhibitor of Metalloproteinase-2IBA
01/2020
1Protein Kinases (Protein Kinase)IBA
11/2019
1N-propionylprocainamideIBA
11/2019
15-nitro-2-(3-phenylpropylamino)benzoic acidIBA
11/2019
1InterleukinsIBA
03/2019
1Oxidants (Oxidizing Agents)IBA
01/2019
1Plasminogen Activator Inhibitor 1IBA
01/2019
1OsteopontinIBA
01/2019
1Fibronectins (Fibronectin)IBA
01/2019
1CXA-10IBA
01/2019
1halofuginoneIBA
05/2017
1Proline (L-Proline)FDA Link
01/2017
1Leucine (L-Leucine)FDA Link
01/2017
1Uremic ToxinsIBA
01/2017
14-cresol sulfateIBA
01/2017
1Glucose (Dextrose)FDA LinkGeneric
01/2015
1Ion Channels (Ion Channel)IBA
07/2014
1AcidsIBA
07/2014
1ChemokinesIBA
07/2014

Therapy/Procedure

6Therapeutics
11/2021 - 11/2010
2Oral Administration
11/2021 - 02/2004
2Nephrectomy
08/2021 - 01/2020